ecancermedicalscience

Case Report

Pegylated Liposomal Doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo

9 Dec 2008
Y Yuan, SJ Orlow, J Curtin, A Downey, F Muggia

Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a ‘Stealth’ (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.

Article metrics: 2155 views
816
1339

Related Articles

Ryan M Kahn, Sushmita Gordhandas, Kiersten Craig, Tanaka K Dune, Kevin Holcomb, Eloise Chapman-Davis, Melissa K Frey
Frederic Ivan Ting, Danielle Benedict Sacdalan, Honey Sarita Abarquez, Arnold John Uson
Milan Terzic, Melanie Norton, Sanja Terzic, Gauri Bapayeva, Gulzhanat Aimagambetova
Mattia Maramai, Fabio Barra, Mario Valenzano Menada, Sara Stigliani, Melita Moioli, Sergio Costantini, Simone Ferrero
Barbara Buonomo, Roberto Orecchia, Federica Tomao, Lino Del Pup, Alex Garcia-Faura, Fedro A Peccatori
Suleiman Ghunaim, Ghina Ghazeeri, Dalia Khalife, Hatem A Azim Jr